Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma

Robert Chen, Suzanne Allibone, Nancy L. Bartlett, Pauline Brice, Andy Chen, Katrina Pose, Lynn Rich, Vijay Bonthapally, Phillip M. Garfin, Michelle Fanale

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are becoming increasingly important and can help inform treatment decisions to enhance care of cancer patients. Objective: The objective was to qualitatively assess HRQoL in long-term survivors treated with BV. Methods: An eight-question survey assessing PRO-related aspects was developed and fielded to a subset of patients with HL or sALCL who remained in long-term follow-up after completing BV treatment in the two pivotal studies. Results: The survey was completed by 25 of 38 patients (12 with HL, 13 with sALCL). The majority of patients reported that their energy level, outlook on life, difficulties with daily activities, ability to participate in physical activities, and overall HRQoL improved compared to those before BV treatment. Limitations: Small sample size and lack of a baseline questionnaire or validated assessment instrument limit broad applicability of these findings to large populations of patients with HL or sALCL. Conclusion: This is the first report of BV PRO data in R/R HL and sALCL. Given the patients’ poor prognostic outcomes before stem cell transplant, these encouraging results warrant formal evaluation of PRO end points in BV trials.

Original languageEnglish (US)
Pages (from-to)2027-2034
Number of pages8
JournalOncoTargets and Therapy
Volume9
DOIs
StatePublished - Apr 6 2016

Fingerprint

Anaplastic Large-Cell Lymphoma
Hodgkin Disease
Quality of Life
Sample Size
Survivors
Patient Reported Outcome Measures
cAC10-vcMMAE
Patient Care
Stem Cells
Therapeutics
Survival Rate
Exercise
Transplants
Population
Surveys and Questionnaires
Neoplasms

Keywords

  • Activities of daily living
  • Brentuximab vedotin
  • Health-related quality of life
  • Patient well-being
  • Pilot study

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. / Chen, Robert; Allibone, Suzanne; Bartlett, Nancy L.; Brice, Pauline; Chen, Andy; Pose, Katrina; Rich, Lynn; Bonthapally, Vijay; Garfin, Phillip M.; Fanale, Michelle.

In: OncoTargets and Therapy, Vol. 9, 06.04.2016, p. 2027-2034.

Research output: Contribution to journalArticle

Chen, R, Allibone, S, Bartlett, NL, Brice, P, Chen, A, Pose, K, Rich, L, Bonthapally, V, Garfin, PM & Fanale, M 2016, 'Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma', OncoTargets and Therapy, vol. 9, pp. 2027-2034. https://doi.org/10.2147/OTT.S96175
Chen, Robert ; Allibone, Suzanne ; Bartlett, Nancy L. ; Brice, Pauline ; Chen, Andy ; Pose, Katrina ; Rich, Lynn ; Bonthapally, Vijay ; Garfin, Phillip M. ; Fanale, Michelle. / Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. In: OncoTargets and Therapy. 2016 ; Vol. 9. pp. 2027-2034.
@article{83ce8274fb75489aa0eb9b66e5468733,
title = "Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma",
abstract = "Background: Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are becoming increasingly important and can help inform treatment decisions to enhance care of cancer patients. Objective: The objective was to qualitatively assess HRQoL in long-term survivors treated with BV. Methods: An eight-question survey assessing PRO-related aspects was developed and fielded to a subset of patients with HL or sALCL who remained in long-term follow-up after completing BV treatment in the two pivotal studies. Results: The survey was completed by 25 of 38 patients (12 with HL, 13 with sALCL). The majority of patients reported that their energy level, outlook on life, difficulties with daily activities, ability to participate in physical activities, and overall HRQoL improved compared to those before BV treatment. Limitations: Small sample size and lack of a baseline questionnaire or validated assessment instrument limit broad applicability of these findings to large populations of patients with HL or sALCL. Conclusion: This is the first report of BV PRO data in R/R HL and sALCL. Given the patients’ poor prognostic outcomes before stem cell transplant, these encouraging results warrant formal evaluation of PRO end points in BV trials.",
keywords = "Activities of daily living, Brentuximab vedotin, Health-related quality of life, Patient well-being, Pilot study",
author = "Robert Chen and Suzanne Allibone and Bartlett, {Nancy L.} and Pauline Brice and Andy Chen and Katrina Pose and Lynn Rich and Vijay Bonthapally and Garfin, {Phillip M.} and Michelle Fanale",
year = "2016",
month = "4",
day = "6",
doi = "10.2147/OTT.S96175",
language = "English (US)",
volume = "9",
pages = "2027--2034",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma

AU - Chen, Robert

AU - Allibone, Suzanne

AU - Bartlett, Nancy L.

AU - Brice, Pauline

AU - Chen, Andy

AU - Pose, Katrina

AU - Rich, Lynn

AU - Bonthapally, Vijay

AU - Garfin, Phillip M.

AU - Fanale, Michelle

PY - 2016/4/6

Y1 - 2016/4/6

N2 - Background: Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are becoming increasingly important and can help inform treatment decisions to enhance care of cancer patients. Objective: The objective was to qualitatively assess HRQoL in long-term survivors treated with BV. Methods: An eight-question survey assessing PRO-related aspects was developed and fielded to a subset of patients with HL or sALCL who remained in long-term follow-up after completing BV treatment in the two pivotal studies. Results: The survey was completed by 25 of 38 patients (12 with HL, 13 with sALCL). The majority of patients reported that their energy level, outlook on life, difficulties with daily activities, ability to participate in physical activities, and overall HRQoL improved compared to those before BV treatment. Limitations: Small sample size and lack of a baseline questionnaire or validated assessment instrument limit broad applicability of these findings to large populations of patients with HL or sALCL. Conclusion: This is the first report of BV PRO data in R/R HL and sALCL. Given the patients’ poor prognostic outcomes before stem cell transplant, these encouraging results warrant formal evaluation of PRO end points in BV trials.

AB - Background: Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are becoming increasingly important and can help inform treatment decisions to enhance care of cancer patients. Objective: The objective was to qualitatively assess HRQoL in long-term survivors treated with BV. Methods: An eight-question survey assessing PRO-related aspects was developed and fielded to a subset of patients with HL or sALCL who remained in long-term follow-up after completing BV treatment in the two pivotal studies. Results: The survey was completed by 25 of 38 patients (12 with HL, 13 with sALCL). The majority of patients reported that their energy level, outlook on life, difficulties with daily activities, ability to participate in physical activities, and overall HRQoL improved compared to those before BV treatment. Limitations: Small sample size and lack of a baseline questionnaire or validated assessment instrument limit broad applicability of these findings to large populations of patients with HL or sALCL. Conclusion: This is the first report of BV PRO data in R/R HL and sALCL. Given the patients’ poor prognostic outcomes before stem cell transplant, these encouraging results warrant formal evaluation of PRO end points in BV trials.

KW - Activities of daily living

KW - Brentuximab vedotin

KW - Health-related quality of life

KW - Patient well-being

KW - Pilot study

UR - http://www.scopus.com/inward/record.url?scp=84964068298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964068298&partnerID=8YFLogxK

U2 - 10.2147/OTT.S96175

DO - 10.2147/OTT.S96175

M3 - Article

VL - 9

SP - 2027

EP - 2034

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -